HOUSTON, May 04, 2022 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company will present four posters on its Multi-Tumor-Associated Antigen (MultiTAA)-specific T cell therapies at the 2022 International Society for Cell & Gene Therapy (ISCT) Annual Meeting, being held May 4-7, 2022, in San Francisco.
“We are excited to present data on our state-of-the-art T cell therapy manufacturing process for our MultiTAA-specific T cell product candidates at ISCT, including improvements resulting in faster manufacturing time and increased potency for our lead product candidate, MT-401, currently in a Phase 2 study for the treatment of post-transplant AML,” said Peter L. Hoang, President & CEO of Marker Therapeutics. “We look forward to sharing additional details on our improved manufacturing process, which we believe has the potential to enhance clinical responses in patients. In addition, we will present more detail on the clinical results from the six-patient safety lead-in stage of our Phase 2 AML trial, previously reported in February 2022, which demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading.”
The four posters will be presented on Thursday, May 5, from 5:45 p.m. – 7:15 p.m. PT.
- MT-401 (multi-tumor associated antigen-specific T cells) utilized for treatment for MRD+ AML patients
Abstract #: 515
Presenter: Shukaib Arslan, MD, City of Hope Comprehensive Cancer Center
- Long-term Characterization of T Cell Product Interactions using in vitro 3D tumor models and the Go-Rex Platform
Abstract #: 506
Presenter: Eric A. Smith, PhD, Marker Therapeutics
- Rapid and Simplified Process for Manufacturing Multi-Tumor-Associated Antigen Specific T Cells
Abstract #: 936
Presenter: Anastasiya Smith, PhD, Marker Therapeutics
- Automating Closed System Purification of White Blood Cells for T Cell Therapy Manufacturing
Abstract #: 937
Presenter: Anastasiya Smith, PhD, Marker Therapeutics
The posters will be available in the Publications section of Marker’s website at https://www.markertherapeutics.com at the beginning of the session.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies and our preclinical pipeline; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the potential commercialization of our current and future product candidates; our manufacturing processes and the efficiencies and cost thereof; our ability to use our cGMP manufacturing facility to support clinical and commercial demand; and our ability to secure additional funding on favorable terms. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investors and Media Contacts
Vice President/Head of Investor Relations, PR & Marketing